Latest Adalimumab Stories

2010-01-27 06:46:00

ABBOTT PARK, Ill., Jan. 27 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2009. Diluted earnings per share, excluding specified items, were $1.18, reflecting 11.3 percent growth, at the high end of Abbott's previous forecast.

2010-01-14 07:00:00

HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA(TM) (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine.

2009-12-23 11:00:00

EXTON, Pa., Dec. 23 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was completed by U.S. Rheumatologists (n=77) in late November 2009.

2009-12-09 07:06:00

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S.

Word of the Day
  • In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
  • In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.
The word 'postliminy' comes from a Latin word meaning 'threshold'.